DOI: 10.1515/mr-2023-0051
Complement-targeted therapy for autoimmune diseases
Cong-Qiu Chu
Division of Arthritis and Rheumatic Diseases,Oregon Health&Science University,Portland,OR 97239,USA;Rheumatology Section,Veterans Affairs Portland Health Care System,Portland,OR 97239,USA
摘要：The success and safety seen in treating complement-mediated hemolysis conditions has sparked the development of targeted therapies for rare autoimmune diseases,with expansion to more common autoimmune conditions.Various classes of drugs,including small molecules,peptides,monoclonal antibodies,and small interfering RNA(siRNA),are undergoing development to specifically address complement activity.A dual approach targeting both complement and other immune components may be required for autoimmune diseases characterized by inflammation and complex pathogenic mechanisms.siRNA,which suppresses complement production,is emerging as a potent therapeutic tool.Combining a complement-blocking siRNA drug with a treatment that reduces autoantibodies could prove clinically feasible and impactful in managing these conditions.
机标关键词：autoimmunecomplementdiseasestargetedtherapy
论文发表日期：2023-12-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：5( 521-525 )
英文信息